Simon Bergqvist

Resensitization to Crizotinib by the Lorlatinib<i>ALK</i>Resistance Mutation L1198F

Alice T. Shaw, Luc Friboulet, Ignaty Leshchiner et al. · New England Journal of Medicine · 2015 · 484 citations · Full text

Medicine, Oncology, Pharmacology +16

Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance

Ping Chen, Nathan V. Lee, Wenyue Hu et al. · Molecular Cancer Therapeutics · 2016 · 422 citations

Medicine, Oncology, Pharmacology +9

Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth

Brion W. Murray, Chuangxing Guo, Joseph Piraino et al. · Proceedings of the National Academy of Sciences · 2010 · 321 citations · Full text

Medicine, Oncology, Pharmacology +15

Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance

Phillip A. Schwartz, Petr Kuzmič, James Solowiej et al. · Proceedings of the National Academy of Sciences · 2013 · 281 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity

Timothy S. Fisher, Cris Kamperschroer, Theodore Oliphant et al. · Cancer Immunology Immunotherapy · 2012 · 163 citations · Full text

Medicine, Immunology, Oncology +12